Answers are grounded in this paper and cite their sources.
Guidelines present how MRI monitors clinical activity in multiple sclerosis, suggesting important research directions.
Serial gadolinium enhanced MRI of the brain detects much clinically silent disease activity in early relapsing-remitting and secondary progressive multiple sclerosis (MS), and thus has an important role in monitoring the effects of therapy. Based on the proceedings of a recent Commission of the European Communities (CEC) workshop and a review of the literature, guidelines are presented for using MRI to monitor treatment trials in MS. The guidelines consider: A) MRI system and techniques; B) patient selection; C) trial design; D) analysis of results. Priorities for future research are also indicated.
No takes yet. Share an insight, caveat, or question.
Miller et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: